Globus Medical, Inc. (GMED) — ESG & Values Scores

Environment story

Globus Medical discloses minimal environmental metrics in its 10-K filing. No Scope 1, 2, or 3 emissions data, renewable energy percentage, or net-zero target year are publicly stated. The company acknowledges handling hazardous and biological materials in manufacturing and cadaveric labs but reports no material environmental liabilities. Manufacturing facilities are distributed across Pennsylvania, Ohio, Texas, Massachusetts, and Costa Rica. Environmental compliance is stated but quantified commitments to decarbonization are absent. The lack of disclosed emissions inventory and climate targets results in significant scoring deductions under the deterministic rubric.

Criticisms on file

FDA Warning Letter (July 16, 2024) - ExcelsiusGPS® robotic system complaint procedures and MDR compliance deficiencies in Audubon, Pennsylvania facility. Letter cited non-conformities in product complaint procedures, complaint investigations, and Medical Device Report procedures including timely reporting. No safety concerns identified with the device itself or manufacturing process.
Source: GMED 10-K Form, Item 1A Risk Factors / Regulatory Compliance section, dated 2026

Disclosed initiatives

Environmental Compliance & Hazardous Materials Management

Company operates facilities handling biological, hazardous and radioactive materials in compliance with federal, state and local environmental laws. Includes cadaveric laboratory operations and allograft tissue processing.
Waste Management & Recycling Programs

Environmental, Health & Safety team oversees recycling and hazardous waste management across global operations.

Social story

Globus Medical reports over 6,000 employees globally as of December 31, 2025. The company describes a non-unionized workforce (except one international market subject to collective bargaining) and emphasizes competitive compensation, comprehensive benefits, talent development, and inclusive culture. CEO-to-worker pay ratio, workforce turnover rate, and detailed diversity breakdowns are not disclosed in the 10-K. Leadership diversity metrics are absent. The company funds Globus Cares, a 501(c)(3) nonprofit supporting spine surgery access in underserved communities since 2009. No documented union-suppression activities, strikes, or major labor disputes are disclosed. Health and safety programs are described as priorities with annual safety campaigns.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Competitive Compensation & Benefits Package

Offerings include competitive pay, annual incentive awards, bonus opportunities tied to individual and company performance, comprehensive health and wellness programs, retirement benefits, paid time off and sick leave.
Talent Development & Professional Growth

Robust onboarding programs, training on business and medical conditions, emphasis on professional development, mentoring, engagement, leadership development, and Individual Development Plans tied to career aspirations.
Inclusive Culture & Diversity

Company recognizes value of diverse backgrounds and experiences for innovation. HR and talent teams actively support professional development across all demographics. Goal to cultivate respectful, inclusive environment where all voices are heard and valued.
Health, Safety & Wellness Programs

Environmental, Health & Safety team develops safety practices, conducts training programs, annual safety campaigns, and monitors compliance to reduce serious injuries. Emphasis on corporate compliance, recycling, hazardous waste management and emergency preparedness.
Globus Cares Foundation

501(c)(3) nonprofit organization founded in 2009. Supports life-changing spine surgery for individuals with limited access to high-quality medical treatment in disadvantaged communities. Provides grants for medical research, education, and charitable endeavors including shelters, food banks, and breast cancer research.
Employee Engagement & Communication

Multiple channels for feedback including open forums with leadership, global intranet, regional/functional meetings, and quarterly Town Halls. Annual input used to strengthen culture and improve engagement.

Governance story

Globus Medical is a Delaware corporation incorporated in March 2003, headquartered in Audubon, Pennsylvania. The company operates a single share class (Class A common stock, $0.001 par value) with no disclosed dual-class voting structure. Board independence percentage is not disclosed in the 10-K. The company is subject to FDA regulations, state medical device licensing, and international regulatory frameworks including EU MDR, UK MHRA, and Japanese PMD Act requirements. The company discloses FDA warning letter compliance obligations but no active antitrust proceedings, material consumer-safety regulatory actions, or shareholder litigation regarding climate proposals. Lobbying expenditures and PAC contributions are not disclosed. The company emphasizes compliance with anti-kickback statutes, False Claims Act, Sunshine Act physician payment transparency, FCPA anti-bribery requirements, and HIPAA privacy rules. Governance disclosure is limited; detailed board composition, independence ratios, and political spending are absent from 10-K.

Criticisms on file

FDA Warning Letter Compliance - ExcelsiusGPS® Product Complaint Procedures. FDA cited deficiencies in response letters to Form 483 observations from February-March 2024 inspection of Audubon facility. Non-conformities included inadequate product complaint procedures, complaint investigations, risk reconciliation, and Medical Device Report procedures including timely reporting for robotic system. FDA letter stated no safety concerns with device or manufacturing process but letter remained open as of February 24, 2026.
Source: GMED 10-K Form, Item 1A Risk Factors, Regulatory Compliance section, dated 2026

Disclosed initiatives

Regulatory Compliance & Quality Systems

Adherence to FDA Quality Management System Regulation (21 CFR Part 820), ISO-13485 for implant suppliers, design controls, and post-market surveillance. Facilities subject to periodic FDA and state inspections.
Anti-Fraud & Anti-Corruption Compliance

Internal policies to comply with federal Anti-Kickback Statute, False Claims Act, Sunshine Act physician payment transparency, FCPA anti-bribery requirements, HIPAA privacy rules, and state anti-fraud statutes.
International Regulatory Alignment

Compliance with EU Medical Device Regulation 2017/745 (MDR), UK MHRA UKCA marking, Japanese PMD Act, Australian, Canadian, Brazilian and other country-specific device registration and approval requirements.
Intellectual Property Protection

3,374 issued U.S. patents (3,333 utility, 41 design) as of December 31, 2025. 832 pending U.S. patent applications. 2,311 issued foreign patents and 401 pending foreign patents. 984 registered trademarks and 199 pending. Use of confidentiality agreements, NDAs, and trade secret protections.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Globus Medical, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Globus Medical, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)